Idorsia stock
Price history
+10.51% over the period1 year: from CHF 3.24 (November 20, 2025) to CHF 3.59 (November 20, 2026), +10.51%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | CHF 3.59 |
| October 30, 2026 | CHF 4.47 |
| September 30, 2026 | CHF 4.65 |
| August 31, 2026 | CHF 4.94 |
| July 31, 2026 | CHF 6.11 |
| June 30, 2026 | CHF 6.86 |
| May 29, 2026 | CHF 4.47 |
| April 30, 2026 | CHF 3.68 |
| March 31, 2026 | CHF 3.47 |
| February 27, 2026 | CHF 3.91 |
| January 30, 2026 | CHF 3.65 |
| December 30, 2025 | CHF 4.26 |
| November 28, 2025 | CHF 3.20 |
| November 20, 2025 | CHF 3.24 |
At a glance
The company
Biopharmaceutical company discovering and developing drugs for CNS, cardiovascular, immunological and orphan diseases
Latest results
Quarter to September 30, 2026 · EPS -CHF 0.17 (estimate -CHF 0.28)
TickerLandia's take on Idorsia
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−52.57% from the 52-week high
Analysts · 3 analysts
Average targetCHF 5.00+39.43% vs. price
Buy 2 · Hold 1 · Sell 0 · Buy
TickerLandia Fingerprint: Idorsia
Compared with similar companies: very low earnings stability and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage55
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 70.6 85 Price/sales 4.79 25 Profitabilitylow24
How much it earns on revenue and capital.
Metric Value Position in group ROE 23.9% 76 Gross margin 32.2% 12 Operating margin −68.4% 16 Net marginabove 100%: likely one-off items −128.8% 4 ROA −20.5% 11 Earnings stabilityvery low17
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 661.4% 22 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthaverage56
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −47.94% 31 Average revenue growth (3 years) +31.46% 61 Revenue growth (year over year) +49.30% 77 Financial strengthlow38
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength · negative shareholders' equity −1.08 96 Interest coverage −8.38 18 Current ratio 0.58 1 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak21
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −36.86% 1 Relative strength (6 months) −17.48% 23 1-year return +10.51% 53 Distance from 200-day average −22.28% 9 Riskvery high80
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 48.0% 93 Volatility (60 days) 48.4% 91 Beta (1 year) 0.84 58
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Idorsia is pricier than similar companies
Idorsia's Forward P/E: 70.6, +35% against the median of a group of 6 similar companies (52.3).
Compared with 6 similar companies
| Metric | Idorsia | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 70.6 | Middle | |
| Operating margin | -68.4% | Middle | |
| ROE | 23.9% | Middle | |
| Debt/equity | -1.08 | Low | |
| Net margin | -128.8% | Low |
Grey band: the middle half of the group; tick: the median; dot: Idorsia. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
CHF 61.92M
Latest quarter · Q3 2026
Net income
-CHF 53.02M
Latest quarter · Q3 2026
Quarterly net margin
-85.6%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- CHF 1.05B
- EPS
- -CHF 1.15
- Volume
- 680.03K
- Daily trading
- €3.62M
How Idorsia is changing
All resultsRevenue grew 25.2% a year on average over the last 5 years
Operating margin rose from −825.2% to −52.8%
Shares outstanding up 50.3% in 5 years
Returns
Idorsia returns
CHF 1,000 invested in Idorsia 5 years ago, on November 22, 2021, would be worth CHF 215 today: −78.51% in total, −26.50% per year. This is the price return only: dividends are excluded.
| Period | Idorsia | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | −15.50% | +0.65% | CHF 845 |
| 6 months | −10.26% | +8.75% | CHF 897 |
| Year to date | −15.72% | +9.83% | CHF 843 |
| 1 year | +10.51% | +16.18% | CHF 1,105 |
| 3 years | +84.09% | +35.68% | CHF 1,841 |
| 5 years | −78.51% | +16.48% | CHF 215 |
Over the last 6 months it has done better than 10% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Idorsia: technical analysis
Idorsia shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 89.2% below its all-time closing high (CHF 33.17, January 24, 2020).
- Trend
- No clear trend
- RSI (14 sessions)
- 29
- Below 30: a strong fall in a short time
- vs 200-session average
- −22.28%
Active signals
Close below the low of the previous 55 sessions.
since November 19, 2026
RSI below 30: the stock has fallen a lot in a short time.
Support and resistance
Price areas where Idorsia has stopped several times in the last year. They describe the chart; they are not forecasts.
- ResistanceCHF 4.14+15.45%2 touches, last on April 28, 2026
- ResistanceCHF 3.98+11.02%3 touches, last on October 19, 2026
- ResistanceCHF 3.83+6.77%4 touches, last on May 20, 2026
- Last priceCHF 3.59
- SupportCHF 3.43−4.48%3 touches, last on April 28, 2026
- SupportCHF 3.30−8.05%2 touches, last on March 6, 2026
- SupportCHF 2.83−21.22%2 touches, last on March 16, 2026
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 0.84
- Volatility (60 sessions, annualised)
- 48.4%
- Largest fall in the last year
- −47.95%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Idorsia: seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for Idorsia has been May: +10.70% on average, positive in 7 years out of 9. The weakest has been October: −10.41% on average, positive in 2 years out of 10. November, the current month, has been positive in 4 years out of 9 (+0.32% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.37% | +5.67% | 6 of 9 |
| February | +8.49% | −8.26% | 3 of 9 |
| March | −4.31% | −1.56% | 3 of 9 |
| April | −0.81% | +0.26% | 5 of 9 |
| May | +10.70% | +4.66% | 7 of 9 |
| June | +5.88% | +3.70% | 5 of 9 |
| July | +2.91% | −5.48% | 3 of 10 |
| August | −2.34% | −3.40% | 3 of 10 |
| September | −5.79% | −6.85% | 3 of 10 |
| October | −10.41% | −12.60% | 2 of 10 |
| November | +0.32% | −2.67% | 4 of 9 |
| December | +6.95% | +10.33% | 5 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Idorsia and its competitors
QUVIVIQ (daridorexant), a treatment for insomnia, is the product through which many people know Idorsia Ltd, a biopharmaceutical company that discovers, develops and commercializes drugs for unmet medical needs.
- Headquarters
- Allschwil, Switzerland
- Employees
- 424
- Founded
- 2017
- Chief executive
- Roland Wandeler
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| IdorsiaIDIA | $1.26B | -68.4% | — | −10.26% |
| Pharma MarPHM | $1.1B | 21.3% | 14.7 | −41.56% |
| Basilea PharmaceuticaBSLN | $1.07B | 24.2% | 18.1 | +35.06% |
| PhilogenPHIL | $905.96M | 79.1% | 3.67 | −5.63% |
| InventivaIVA | $890.8M | -5,980.9% | — | −33.75% |
| Pharming GroupPHARM | $841.25M | 12.8% | 36.1 | −2.57% |
Same industry or related industries, similar size. Compare Idorsia with its competitors · Full profile
